Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Dec 31;13(12):3835-3837.
doi: 10.21037/tlcr-24-864. Epub 2024 Dec 27.

Finding the right HARMONi-A

Vladmir Cláudio Cordeiro de Lima  1 , Helano Carioca Freitas  1
Affiliations
Editorial

Finding the right HARMONi-A

Vladmir Cláudio Cordeiro de Lima et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Non-small cell lung cancer (NSCLC); epidermal growth factor receptor-mutant (EGFR-mutant); ivonescimab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-864/coif). V.C.C.d.L. received a consulting fee from Roche; received honoraria for lectures, presentations, manuscript writing, and educational events from Roche Brasil, Amgen, MSD Brasil, BMS Brasil, Jassen, Daichii-Sankyo, Pfizer, and Astra Zeneca; and received financial support to attend scientific meetings and travels from Astra Zeneca, Roche, and Janssen. He also participated in advisory boards from Roche Brasil, Amgen, MSD Brasil, BMS Brasil, Jassen, Daichii-Sankyo, Pfizer, Astra-Zeneca, and Pfizer. H.C.F. has received payment or honoraria for lectures, presentations, speaker bureaus, or educational from MSD, Roche, Lilly, Pfizer, Takeda, BMS, Amgen, AstraZeneca, and Merck. Support for attending meetings or travel has been provided by BMS, MSD, Pfizer, Roche, AZ, Takeda, and Sanofi. He also participates in advisory boards for MSD, Pfizer, Lilly, Takeda, Roche, BMS, and Amgen. Additionally, his spouse works in the clinical research department at AstraZeneca. The authors have no other conflicts of interest to declare.

Comment on

  • Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.
    HARMONi-A Study Investigators; Fang W, Zhao Y, Luo Y, Yang R, Huang Y, He Z, Zhao H, Li M, Li K, Song Q, Du X, Sun Y, Li W, Xu F, Wang Z, Yang K, Fan Y, Liu B, Zhao H, Hu Y, Jia L, Xu S, Yi T, Lv D, Lan H, Li M, Liang W, Wang Y, Yang H, Jia Y, Chen Y, Lu J, Feng J, Liu C, Zhou M, Zhou J, Liu X, Zhou N, He M, Dong X, Chen H, Chen Y, Su H, Li X, Zhang Z, Yang L, Cheng Y, Chen L, Hou X, Zhang Y, Guo J, Wang Z, Lu H, Wu D, Feng W, Li W, Huang J, Wang Y, Song X, Peng J, Liu L, Guo Y, Li W, Lu D, Hu M, Wang ZM, Li B, Xia M, Zhang L. HARMONi-A Study Investigators, et al. JAMA. 2024 Aug 20;332(7):561-570. doi: 10.1001/jama.2024.10613. JAMA. 2024. PMID: 38820549 Free PMC article. Clinical Trial.

References

    1. Lisberg A, Cummings A, Goldman JW, et al. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol 2018;13:1138-45. 10.1016/j.jtho.2018.03.035 - DOI - PMC - PubMed
    1. Yang JC, Lee DH, Lee JS, et al. Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer. J Clin Oncol 2024;42:4029-39. 10.1200/JCO.23.02747 - DOI - PMC - PubMed
    1. Mok T, Nakagawa K, Park K, et al. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. J Clin Oncol 2024;42:1252-64. 10.1200/JCO.23.01017 - DOI - PMC - PubMed
    1. Larsen AK, Ouaret D, El Ouadrani K, et al. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther 2011;131:80-90. 10.1016/j.pharmthera.2011.03.012 - DOI - PubMed
    1. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013;39:61-73. 10.1016/j.immuni.2013.07.005 - DOI - PMC - PubMed

LinkOut - more resources